Collegium Pharmaceutical, Inc. COLL
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · collegiumpharma.com
Collegium Pharmaceutical, Inc. is a Massachusetts-based biopharmaceutical company with a portfolio of responsible pain management medications, including Xtampza ER (abuse-deterrent oxycodone), Nucynta ER/IR (tapentadol), Belbuca (buprenorphine buccal film) and Symproic, as well as a growing neuropsychiatry business driven by Jornay PM, an ADHD treatment. The company announced in July 2026 that it will relocate its headquarters to downtown Boston in early 2027.
Key ratios
CashFromOperationsYoYGrowth TTM 0.67
CashFromOperationsYoYGrowth 2025 0.61
CashFromOperationsYoYGrowth 2024 -0.25
CashFromOperationsYoYGrowth 2023 1.21
DilutedEPSYoYGrowth TTM 0.31
DilutedEPSYoYGrowth 2025 -0.07
DilutedEPSYoYGrowth 2024 0.44
FreeCashFlowOnSale TTM 0.41
FreeCashFlowOnSale 2025 0.42
FreeCashFlowOnSale 2024 0.32
FreeCashFlowOnSale 2023 0.48
NetIncomeMargin TTM 0.09
NetIncomeMargin 2025 0.08
NetIncomeMargin 2024 0.11
NetIncomeMargin 2023 0.09
ReturnOnAssets TTM 0.08
ReturnOnAssets 2025 0.07
ReturnOnAssets 2024 0.09
ReturnOnAssets 2023 0.09
ReturnOnEquity TTM 0.27
ReturnOnEquity 2025 0.24
ReturnOnEquity 2024 0.33
ReturnOnEquity 2023 0.25
TotalRevenueYoYGrowth TTM 0.2
TotalRevenueYoYGrowth 2025 0.24
TotalRevenueYoYGrowth 2024 0.11
TotalRevenueYoYGrowth 2023 0.22